Moderate to Severe Psoriatic Arthritis study: DDY391
Official title A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis
ClinicalTrials.gov ID: NCT07801495
What this study is testing
What is DDY391?
DDY391 is an investigational medicine being studied for moderate to severe psoriatic arthritis.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether DDY391 helps reduce arthritis symptoms and is safe to use. It also looks at how different amounts of the drug affect results.
- Who it's for
- You may be able to join if you have moderate to severe psoriatic arthritis and meet the study’s health criteria.
- What's involved
- You will receive the drug at different doses during the study. You will have regular check‑ins and give blood samples to help doctors see how the drug works.
- Time commitment
- The study lasts about 6 months, with several visits to the clinic for dosing and monitoring.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 100
You may be able to join if
- Female or male participants at least 18 years of age.
- Diagnosis of PsA and meeting classification criteria for Psoriatic arthritis (CASPAR) at screening.
- Moderate to severe PsA at screening and baseline. Key
You likely can't join if
- Presence of inflammatory conditions other than psoriasis or PsA including but not limited to those associated with arthralgia or arthritis (e.g...
- Use of bDMARD treatment within 4 weeks or 5 half-lives of randomization, whichever is longer
- Prior use of JAK inhibitors or TYK2 inhibitors (e.g., deucravacitinib).
- Previous treatment with any cell-depleting therapies, including but not limited to anti-CD20, unless ≥ 12 months prior to baseline.
- History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for basal...
- Any active viral, bacterial or other infections at the time of screening or randomization, or history of recurrent clinically significant infection...
The study team makes the final eligibility decision.
Where it is enrolling
- Huntington Beach, California, United States
- Duncansville, Pennsylvania, United States
- Philadelphia, Pennsylvania, United States
- Memphis, Tennessee, United States
- Colleyville, Texas, United States
- Corpus Christi, Texas, United States
- Katy, Texas, United States
- San Antonio, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 100 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Huntington Beach, California, United States; Duncansville, Pennsylvania, United States; Philadelphia, Pennsylvania, United States; Memphis, Tennessee, United States; Colleyville, Texas, United States; Corpus Christi, Texas, United States and 2 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.